Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03582124 · ClinicalTrials.gov registry record · Phase 1
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
A Phase 1 study of Stage IV Lung Cancer AJCC v8 and Lung Carcinoma, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03582124: Recruiting Phase 1 study of Stage IV Lung Cancer AJCC v8 and Lung Carcinoma, sponsored by Stanford University.
NCT03582124 is a Phase 1 study of Stage IV Lung Cancer AJCC v8 and Lung Carcinoma that is actively recruiting participants, run by Stanford University. The registered enrollment target is 30 participants, below the 98-participant average among 81 other Stage IV Lung Cancer AJCC v8 trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03582124, a Phase 1 study of Stage IV Lung Cancer AJCC v8 and Lung Carcinoma, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I/II trial studies the best dose and timing of panitumumab-IRDye800 in detecting cancer in participants with lung cancer during the surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and IRDye800CW, an investigational dye that can be seen using a special camera. Panitumumab-IRDye800 may attach to tumor cells and make them more visible during surgery in patients with lung cancer.
Primary Outcome
The TBR is defined as the near-infrared fluorescence signal of tumor or lymph node tissue compared to normal adjacent tissue measured in ex vivo tissues. Outcomes will be reported as the TBR (mean) and standard deviation for each dose group and timing group (1-2 days or 3-5 days prior to surgery).
Conditions Studied
Interventions
- PROCEDURE Therapeutic Conventional Surgery
- DRUG Panitumumab-IRDye800
- PROCEDURE Near-Infrared Fluorescence Imaging
- OTHER Pharmacokinetic Study
Study Locations (1)
California
- Stanford University, School of Medicine - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-07-19 |
| Est. Completion | 2026-09 |
| Phase | Phase 1 |
What NCT03582124 shows while recruiting
NCT03582124 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 98-participant average among 81 other Stage IV Lung Cancer AJCC v8 trials with a reported enrollment target (69% lower).
The record links to 5 conditions, with Stage IV Lung Cancer AJCC v8 appearing as the primary indexed condition, and to 4 interventions - of which Therapeutic Conventional Surgery is the first listed.
NCT03582124 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03582124 about?
NCT03582124 is a clinical study titled "Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery". This phase I/II trial studies the best dose and timing of panitumumab-IRDye800 in detecting cancer in participants with lung cancer during the surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and IRDye800CW, an investigational dye that can be seen using a special camer...
What is the current status of trial NCT03582124?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2018-07-19. Estimated completion is 2026-09.
What conditions does trial NCT03582124 study?
This clinical trial studies the following conditions: Stage IV Lung Cancer AJCC v8, Lung Carcinoma, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Metastatic Malignant Neoplasm in the Lung.
What interventions are being tested in trial NCT03582124?
The interventions under investigation include: Therapeutic Conventional Surgery (PROCEDURE), Panitumumab-IRDye800 (DRUG), Near-Infrared Fluorescence Imaging (PROCEDURE), Pharmacokinetic Study (OTHER).
Who is sponsoring clinical trial NCT03582124?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03582124 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Lung Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03582124's enrollment target sits among peer trials
30 48th of 81 higher than 30 of 81 other Stage IV Lung Cancer AJCC v8 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage IV Lung Cancer AJCC v8 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
RECRUITING · Phase 1
-
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
RECRUITING · Phase 1
-
Gilteritinib for the Treatment of ALK NSCLC
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI